Function of the Escherichia coli msbB Gene, a Multicopy Suppressor of htrB Knockouts, in the Acylation of Lipid A
ACYLATION BY MsbB FOLLOWS LAURATE INCORPORATION BY HtrB*

(Received for publication, January 21, 1997)

Tony Clementz , Zhimin Zhou and Christian R. H. Raetz Dagger

From the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES


ABSTRACT

Overexpression of the Escherichia coli msbB gene on high copy plasmids suppresses the temperature-sensitive growth associated with mutations in the htrB gene. htrB encodes the lauroyl transferase of lipid A biosynthesis that acylates the intermediate (Kdo)2-lipid IVA (Brozek, K. A., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 15410-15417). Since msbB displays 27.5% identity and 42.2% similarity to htrB, we explored the possibility that msbB encodes a related acyltransferase. In contrast to htrB, extracts of strains with insertion mutations in msbB are not defective in transferring laurate from lauroyl acyl carrier protein to (Kdo)2-lipid IVA. However, extracts of msbB mutants do not efficiently acylate the product formed by HtrB, designated (Kdo)2-(lauroyl)-lipid IVA. Extracts of strains harboring msbB+ bearing plasmids acylate (Kdo)2-(lauroyl)-lipid IVA very rapidly compared with wild type. We solubilized and partially purified MsbB from an overproducing strain, lacking HtrB. MsbB transfers myristate or laurate, activated on ACP, to (Kdo)2-(lauroyl)-lipid IVA. Decanoyl, palmitoyl, palmitoleoyl, and (R)-3-hydroxymyristoyl-ACP are poor acyl donors. MsbB acylates (Kdo)2-(lauroyl)-lipid IVA about 100 times faster than (Kdo)2-lipid IVA. The slow, but measurable, rate whereby MsbB acts on (Kdo)2-lipid IVA may explain why overexpression of MsbB suppresses the temperature-sensitive phenotype of htrB mutations. Presumably, the acyloxyacyl group generated by excess MsbB substitutes for the one normally formed by HtrB.


INTRODUCTION

The htrB gene was first described by Karow and Georgopoulos (1, 2) as essential for rapid growth of Escherichia coli on nutrient broth above 33 °C. At elevated temperatures, peculiar morphological changes are observed in htrB-deficient strains, including bulging of the cell surface and filamentation (1-3). At permissive temperatures, htrB mutants display increased resistance to bile salts (3). Based on these phenotypes, Karow and Georgopoulos (1, 3-5) suggested function(s) for htrB in cell envelope assembly, including possible roles in peptidoglycan, lipopolysaccharide, and fatty acid biosynthesis.

We have recently demonstrated (6) that the htrB gene of E. coli encodes the lauroyl transferase that acylates the key lipid A biosynthesis intermediate (Kdo1)2-lipid IVA (7) (Fig. 1). This conclusion is based on assays of extracts prepared from htrB-deficient mutants, in which lauroyl transferase activity is undetectable (6). Conversely, cells overexpressing the htrB gene on hybrid plasmids overproduce the transferase several hundredfold (6). We have purified the overproduced enzyme to homogeneity and have shown by N-terminal sequencing that htrB is indeed the structural gene for the lauroyl transferase.2 Identification of htrB as the lauroyl transferase is further supported by fatty acid analyses of lipopolysaccharide isolated from htrB-deficient strains of E. coli, in which the amount of laurate is reduced (4). Lipid A from htrB-deficient Hemophilus influenzae is also under-acylated (8).


Fig. 1. Kdo-dependent "late" acylations of lipid A precursors in extracts of E. coli. The acylation catalyzed by E. coli HtrB is 8-fold selective for laurate over myristate (6), consistent with the composition of the acyloxyacyl residues of lipid A isolated from cells (6). The MsbB-catalyzed acylation of these precursors is 100-fold selective for the penta-acylated (Kdo)2-(lauroyl)-lipid IVA (generated by HtrB) over the tetra-acylated precursor, (Kdo)2-lipid IVA. In extracts, however, MsbB is only slightly selective for myristate over laurate. The possibility that HtrB can function on the (Kdo)2-[myristoyl]-lipid IVA generated at a slow rate by MsbB from myristoyl-ACP and (Kdo)2-lipid IVA has not been examined (as indicated by the question mark). The proposed structures of the lipids generated by HtrB and MsbB are surmised based on what is known about the lipid A structure of E. coli (11, 25-28). Unequivocal analyses to establish the structures of these acylation products of (Kdo)2-lipid IVA generated in vitro have not yet been carried out.
[View Larger Version of this Image (29K GIF file)]


Karow and Georgopoulos (3, 5) identified several genes that, when introduced on hybrid plasmids, suppress the temperature-sensitive growth associated with htrB mutations. The msbA suppressor encodes a putative transport protein with a remarkable similarity to the mammalian mdr genes (5). Most Mdr proteins pump hydrophobic drugs out of animal cells, but some are involved in secretion of phospholipids into bile (9). Although the biochemical function of msbA is unknown, the sequence similarity of msbA to mdr suggests that MsbA might be involved in a translocation process, such as the movement of newly made lipid A from the cytoplasmic surface of the inner membrane to the periplasm (10-12). Whatever its role, the msbA gene is essential for growth (5).

A second suppressor gene, designated msbB, was found to have 27.5% sequence identity and 42.2% similarity to htrB (3) suggesting a biochemical function related to htrB. MsbB reverses the temperature sensitivity associated with htrB mutations when introduced on plasmids that are maintained at high copy number (3). The msbB gene itself is not essential for growth (3). MsbB knockouts greatly reduce the amount of myristate attached lipid A, but they do not affect the laurate content (13). Lipopolysaccharide isolated from msbB mutants contains penta-acylated lipid A (designated (Kdo)2-(lauroyl)-lipid IVA in Fig. 1) (13). MsbB was discovered independently by Somerville et al. (13), who found that whole E. coli cells harboring msbB insertions are orders of magnitude less immunostimulatory than are wild-type cells.

Using direct enzymatic assays, we now demonstrate that the msbB gene of E. coli encodes a distinct, late-functioning acyltransferase of lipid A assembly (7). MsbB functions optimally after laurate incorporation by HtrB has taken place (Fig. 1). The slow, but significant, rate at which MsbB acylates (Kdo)2-lipid IVA explains why msbB+ works only as a high multi-copy suppressor of htrB mutations (3). Our findings support the view that at least one acyloxyacyl residue must be present on a significant fraction of the lipid A moieties of E. coli to allow rapid growth above 33 °C. A preliminary abstract of our findings has appeared (14).


EXPERIMENTAL PROCEDURES

Materials

[gamma -32P]ATP was obtained from DuPont NEN. Pyridine, chloroform, methanol, and 88% formic acid were from Fisher. All detergents were of high quality grade (peroxide- and carbonyl-free). Triton X-100 was from Pierce, and Thesit was from Sigma. Acyl carrier protein was purchased from Sigma. Other items were obtained from the following companies: 0.25-mm glass-backed silica gel 60 thin layer chromatography plates (E. Merck), yeast extract and Tryptone (Difco), and DEAE-Sepharose CL-6B (Pharmacia Biotech Inc.).

Bacterial Strains and Plasmids

Strains used in this study are derivatives of E. coli K12, and their genotypes are listed in Table I. Cultures were grown in Luria broth, consisting of 5 g of NaCl, 5 g of yeast extract, and 10 g of Tryptone per liter (15). Antibiotics were added, when required, at 100 µg/ml for ampicillin, 12 µg/ml for tetracycline, and 10 µg/ml for chloramphenicol.

Table I.

Plasmids and E. coli K12 strains used in this study


Strain Relevant genotype Source

W3110 Wild-type (htrB+ msbB+), F +, lambda - E. coli Genetic Stock Center, Yale University
XL1-Blue htrB+ msbB+ Stratagene
MLK1067 W3110 msbB1::Omega Cam Ref. 3
MLK53 W3110 htrB1::Tn10 Ref. 1
MLK986 MLK53msbB1::Omega Cam Ref. 3
pKS12 pBluescript carrying htrB+ Ref. 1
pBS233 pBluescript carrying msbB+ Ref. 3

Recombinant DNA Techniques

Plasmid DNAs were isolated using the Wizard miniprep kit (Promega). Other recombinant DNA techniques were performed as described previously (16).

Isolation and Preparation of Substrates

Lipid IVA (17), (Kdo)2lipid IVA (18, 19), [4'-32P]lipid IVA (20, 21), and (Kdo)2-[4'-32P]lipid IVA (18, 19) were prepared as described previously. (Kdo)2-(lauroyl)-[4'-32P]lipid IVA was synthesized from lauroyl-ACP and (Kdo)2-[4'-32P]lipid IVA using a DEAE-Sepharose purified HtrB that was isolated from an msbB-deficient strain (MLK1067) containing the htrB overexpressing plasmid, pKS12 (6). The preparative reaction contained 50 mM HEPES, pH 7.5, 0.2% Triton X-100, 50 µM (Kdo)2-[4'-32P]lipid IVA (2 × 103 dpm/nmol), 50 µM lauroyl-ACP, 5 mM MgCl2, 50 mM NaCl, and 8 µg of lauroyl transferase (specific activity, 2200 nmol × min-1 × mg-1) per ml. The total reaction volume was 150 µl. After incubation at 30 °C for 30 min, the reaction mixture was applied as a single line onto a 20 × 20-cm Silica Gel 60 thin layer chromatography plate. After air drying, the plate was developed to the top in the solvent chloroform, pyridine, 88% formic acid, water (30:70:16:10, v/v). The product was detected by a brief autoradiography, and the region of the silica plate containing the desired, more rapidly migrating product was scraped off into a scintered glass funnel. The silica chips were washed once with 4 ml of chloroform. The product, (Kdo)2-(lauroyl)-[4'-32P]lipid IVA, was then eluted with three 3.8-ml portions of a single phase, acidic Bligh and Dyer solvent mixture consisting of chloroform, methanol, 0.1 M HCl (1:2:0.8, v/v) (22). The eluted material (12 ml) was converted to a two-phase, acidic Bligh and Dyer system by the addition of 3 ml each of chloroform and 0.1 M HCl. The tube was mixed vigorously, and the phases were separated by a brief centrifugation. The lower phase was transferred to a new glass tube, and 18 drops of pyridine were added before the solvent was evaporated under a stream of nitrogen. The dried lipid was resuspended in 10 mM Tris chloride, pH 7.5, containing 1 mM EDTA. It was stored at -80 °C and was resuspended by brief (1 min) sonic irradiation prior to use.

Acyl-ACPs containing various acyl chains were synthesized from the corresponding free fatty acids and acyl carrier protein using solubilized membranes from the acyl-ACP synthase overproducing strain, E. coli LCH109/pLCH5/pGP1-2, as described previously (6).

Preparation of Cell-free Extracts, Membranes, and Soluble Fractions

Crude cell-free extracts were made from 1-2 liters of logarithmically growing cultures. After harvesting by low speed centrifugation at 2 °C, cells were washed once in 30 mM HEPES, pH 7.5, containing 1 mM EDTA and 1 mM EGTA (half the volume of the original culture). The washed cell pellet was resuspended in 30 mM HEPES, pH 7.5, containing 1 mM EDTA and 1 mM EGTA (a volume approximately equal to the volume of the cell pellet). Cells were broken using an ice-cold French pressure cell (SLM Instruments, Urbana, IL) at 20,000 psi. The broken cell suspension was adjusted to 10 mM MgSO4, and DNase I was added to 1 µg/ml. After a brief sonic irradiation on an ice water bath to decrease the viscosity, the suspension was incubated for 30 min at 30 °C. Unbroken cells were removed by centrifugation at 1,000 × g for 10 min. Membranes and soluble fractions were separated by centrifugation at 150,000 × g for 60 min. The supernatant was centrifuged a second time to remove residual contaminating membranes. The membrane pellet was resuspended in 25 ml of 30 mM HEPES, pH 7.5, containing 1 mM EDTA and 1 mM EGTA, and it was centrifuged again as above to generate the final, washed membrane fraction (~40 mg/ml). The membrane suspension was stored at -80 °C.

Protein concentrations were determined with the bicinchoninic assay (Pierce), using bovine serum albumin as the standard (23).

Assay for Acyl-ACP-dependent Acylation of Kdo-containing Precursors

HtrB-catalyzed acylation was assayed using Method I described earlier (6). In most cases, the reaction mixture contained 50 mM HEPES, pH 7.5, 0.1% Triton X-100, 25 µM (Kdo)2-[4'-32P]lipid IVA (~2 × 103 dpm/nmol), 25 µM lauroyl-ACP, 0.1 mg/ml bovine serum albumin, and 0.1-1000 µg/ml enzyme at 30 °C in a final volume of 10-20 µl. With highly purified preparations of HtrB, enzyme stability is increased by including 50 mM NaCl and 5 mM MgCl2 in the assay mixture (6). The MsbB-catalyzed acylation of the product generated by HtrB, designated (Kdo)2-(lauroyl)-[4'-32P]-lipid IVA, was assayed in a reaction mixture containing 50 mM HEPES, pH 7.5, 0.1% Triton X-100, and 0.1 mg/ml bovine serum albumin. Unless otherwise indicated, 25 µM (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (~2 × 103 dpm/nmol) was used as the acceptor, and 25 µM myristoyl-ACP was the donor. Under these conditions, MsbB displays a slight kinetic preference for myristoyl-ACP over lauroyl-ACP. MsbB functions about 100-fold more rapidly with (Kdo)2-(lauroyl)-[4'-32P]lipid IVA than with (Kdo)2-[4'-32P]lipid IVA as the acceptor. Since studies using partially purified MsbB showed a stabilizing effect of sodium chloride, 50 mM NaCl was also included in the reaction in some experiments. MgCl2 inhibited MsbB slightly. Reactions were stopped by spotting a 4-5-µl sample onto a Silica Gel 60 thin layer chromatography plate. After air drying and developing the thin layer chromatography plate in the solvent chloroform, pyridine, 88% formic acid, water (30:70:16:10, v/v), the plates were exposed to a PhosphorImager screen. The amount of radioactivity present in the labeled spots corresponding to substrate and product were quantitated using a Molecular Dynamics Imager. The specific activity of both HtrB and MsbB was expressed in terms of nmol/min/mg protein.

Analysis of the Lipid A 4'-Monophosphates Extracted from 32Pi-labeled Cells

Cells were grown and labeled by the method of Galloway and Raetz (24), with several modifications. Briefly, bacteria from 30 °C overnight cultures were inoculated into 20 ml of fresh LB broth and grown for several hours at 30 °C until A600 had reached ~0.1. Next, two 5.0-ml portions of each culture were transferred into two new culture tubes, and 32Pi (5 µCi/ml) was added to both. One was grown for 3 h at 30 °C, and the other was grown for 3 h at 42 °C. 32P-Labeled cells were washed twice with 5.0 ml of phosphate-buffered saline, pH 7.4, and resuspended in 0.8 ml of the same buffer. Washed cells were extracted at room temperature for 60 min with a single phase Bligh and Dyer mixture, formed by the addition of 2 ml of methanol and 1 ml of chloroform. After centrifugation in a clinical centrifuge at top speed for 20 min, the pellets were recovered and washed once with 5.0 ml of a single phase of Bligh and Dyer mixture, consisting of chloroform/methanol/water (1:2:0.8, v/v). The pellets were resuspended in 3.6 ml of 0.2 M HCl by sonic irradiation in a bath. The resuspended pellets were incubated at 100 °C for 90 min. The acid-hydrolyzed material was converted to a two-phase Bligh and Dyer system by addition of 4 ml of chloroform and 4 ml of methanol. After centrifugation at low speed, the upper phases were removed, and the lower phases were washed twice with 4.0 ml of pre-equilibrated acidic upper phase of a two-phase Bligh and Dyer system, generated by mixing chloroform, methanol, 0.2 M HCl (2:2:1.8, v/v). The washed lower phases were dried under a nitrogen stream. The lipid A 4'-monophosphates were redissolved in 100 µl of chloroform/methanol (4:1, v/v), and approximately 1000 cpm of the samples was applied to each lane of a Silica Gel 60 thin layer chromatography plate. The plate was developed in the solvent of chloroform, pyridine, 88% formic acid, water (50:50:16:5, v/v). The plate was dried and exposed overnight to a PhosphorImager screen.


RESULTS

Activity of the htrB Encoded Lauroyl Transferase of E. coli Is Not Reduced by msbB Insertion Mutations

Extracts of strains bearing htrB mutations do not catalyze lauroyl-ACP-dependent acylation of (Kdo)2-[4'-32P]lipid IVA, as shown in Fig. 2 by the absence of (Kdo)2-(lauroyl)-lipid IVA formation (product a in lane 2). The transfer of laurate from lauroyl-ACP to (Kdo)2-[4'-32P]lipid IVA was efficient in extracts of strains harboring an insertion in msbB (Fig. 2, lane 6), as in the wild type (Fig. 2, lane 4). A similar pattern was observed when myristoyl-ACP was substituted for lauroyl-ACP (not shown), except that the initial rates of (Kdo)2-[4'-32P]lipid IVA acylation were 5-10-fold slower with myristoyl-ACP, given the selectivity of HtrB for laurate (6).


Fig. 2. Acylation of (Kdo)2-[4'-32P]lipid IVA in cell-free extracts of E. coli W3110, MLK53(htrB-), and MLK1067(msbB-). Crude cell-free extracts (1.0 mg/ml) from strain MLK53 (lanes 2 and 3), W3110 (lanes 4 and 5), or MLK1067 (lanes 6 and 7) were incubated together with 25 µM (Kdo)2-[4'-32P]lipid IVA (2 × 103 dpm/nmol) in 50 mM HEPES, pH 7.5, and 0.1% Triton X-100 in a total volume of 20 µl. The reactions of Lanes 1, 2, 4, and 6 also contained 25 µM lauroyl-ACP. The reactions of lanes 3, 5, and 7 contained no added acyl-ACP. No cell extract was added to the reaction in lane 1. After incubation for 30 min at 37 °C, 5-µl portions of each reaction mixture were spotted onto a Silica Gel 60 thin layer chromatography plate. The plate was developed in CHCl3, pyridine, 88% formic acid, water (30:70:16:10, v/v). Radioactively labeled compounds were detected, and the extent of conversion was measured with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Arrows indicate the substrate (Kdo)2-[4'-32P]lipid IVA and product a [(Kdo)2-(lauroyl)-[4'-32P]lipid IVA] of the reaction.
[View Larger Version of this Image (80K GIF file)]


Acylation of (Kdo)2-[4'-32P]Lipid IVA by Membranes of Wild-type Cells Overexpressing Either htrB+ or msbB+

In crude extracts or membrane preparations from wild-type cells one observes two distinct acylations of (Kdo)2-[4'-32P]lipid IVA (7). With lauroyl-ACP as the donor, the first acylation is relatively rapid compared with the second (7). With myristoyl-ACP, the first acylation is 5-10-fold slower than with lauroyl-ACP, but the second acylation is slightly faster than with lauroyl-ACP (7). Given that purified HtrB catalyzes only one rapid acylation of (Kdo)2-[4'-32P]lipid IVA (6), it seemed plausible that MsbB might encode the second acyltransferase (Fig. 1) that we previously observed in cell extracts (7).

To approach this problem, we initially incubated membranes of wild-type cells that overexpress either htrB+ or msbB+ with (Kdo)2-[4'-32P]lipid IVA and lauroyl-ACP. As shown in Fig. 3, panel B, overexpression of htrB+ in the presence of msbB+ on the chromosome resulted in very rapid formation and accumulation of a monoacylated product at the relatively low extract concentrations employed (4 µg/ml). Alternatively, overexpression of msbB+ in the presence of htrB+ on the chromosome (Fig. 3, panel A) did not increase the overall extent of (Kdo)2-[4'-32P]lipid IVA acylation compared with wild-type (hence the need to use 100 µg/ml membranes), but it did result in the accumulation of the diacylated material (product b) at the expense of the monoacylated product a. The difference between HtrB and MsbB overproduction in a wild-type background is especially apparent when comparing the product distribution at the 40-min time point in panel A of Fig. 3 (excess MsbB) to the 10-min time point in panel B of Fig. 3 (excess HtrB). In both cases the conversion of substrate to product is similar (~30%), but diacylated material is generated in strains overproducing MsbB, whereas monoacylated product is formed when HtrB is overproduced. The results of Fig. 3 provide support for the idea that MsbB catalyzes the second acylation and can use lauroyl-ACP as the donor under the in vitro assay conditions employed.


Fig. 3. Acylation of (Kdo)2-[4'-32P]lipid IVA by membranes of the MsbB overproducing strain pBS233/XL1 and of the HtrB overproducing strain pKS12/XL1. Membranes of pBS233/XL1 were used at a protein concentration of 100 µg/ml (panel A). Membranes of pKS12/XL1 were used at a protein concentration of 4 µg/ml (panel B). Both kinds of membranes were incubated at 37 °C with 25 µM lauroyl-ACP and 25 µM (Kdo)2-[4'-32P]lipid IVA (2 × 103 dpm/nmol) in 50 mM HEPES, pH 7.5, containing 0.1% Triton X-100 in a total volume of 75 µl. At the times indicated, 5 µl of each reaction mixture was spotted onto a Silica Gel 60 thin layer chromatography plate. The plate was developed, and the radioactive spots were detected as in Fig. 2. Arrows indicate the substrate (Kdo)2-[4'-32P]lipid IVA and the two predominant acylation products (a and b) that are observed in unfractionated systems.
[View Larger Version of this Image (45K GIF file)]


Acylation by MsbB Follows HtrB-catalyzed Acylation of (Kdo)2-[4'-32P]Lipid IVA

To evaluate further the function of MsbB and its relationship to HtrB, we prepared membranes from strains of msbB or htrB-deficient cells overexpressing htrB and msbB, respectively (6). In this way, we could study cell extracts that contained only one or the other enzyme.

As shown in Fig. 4, panel A, membranes of strain MLK53/pBS233 (containing only msbB+) did not catalyze any measurable acylation of (Kdo)2-[4'-32P]lipid IVA under the conditions employed. Membranes of cells containing only HtrB (Fig. 4, panel B) catalyzed mainly the formation of product a. In Fig. 4, panel A, the (Kdo)2-[4'-32P]lipid IVA and acyl-ACP were first preincubated for 60 min with 10 µg/ml membranes of MLK53/pBS233. At time 0, a second 60-min incubation was started. Samples were then withdrawn during the second incubation period for product analysis at the indicated times. In Fig. 4, panels B and C, membranes of strain MLK1067/pKS12 (containing only htrB+) were preincubated for 60 min with (Kdo)2-[4'-32P]lipid IVA and acyl-ACP to generate significant amounts of (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (product a). At time 0, only a small volume of buffer was added to the reaction mixture in panel B. In panel C, a 10 µg/ml portion of membranes of MLK53/pBS233 (containing only msbB+) was added at time 0. The incubations were continued for another 60 min and analyzed as in panel A. The system containing only HtrB (panel B) catalyzed the formation of more product a, whereas the system containing both HtrB and MsbB (panel C) resulted in very rapid accumulation of the diacylated product b derived from product a. These findings show that MsbB functions efficiently only after HtrB-catalyzed acylation of (Kdo)2-[4'-32P]lipid IVA has taken place (Fig. 4, panel A compared with panel C).


Fig. 4. MsbB-catalyzed acylation of (Kdo)2-[4'-32P]lipid IVA is accelerated by preincubation with HtrB. Membranes (10 µg/ml) of pKS12/MLK1067 (an HtrB over-producer lacking MsbB) were incubated with (Kdo)2-[4'-32P]lipid IVA as described in Fig. 3 but with both 25 µM lauroyl-ACP and 25 µM myristoyl-ACP as acyl donors in a total volume of 80 µl. After 60 min of preincubation to allow the HtrB-catalyzed synthesis of (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (product a), the reaction was split into two equal portions. To one portion (panel C) membranes (10 µg/ml final concentration) of pBS233/MLK53 (an MsbB overproducer lacking HtrB) were added in 4 µl. To the second portion (panel B) a corresponding volume of buffer was added. The incubation was continued for another 60 min at 37 °C. A third reaction mixture (panel A) with identical concentrations of substrates and buffers, but containing only membranes (10 µg/ml) of pBS233/MLK53 (an MsbB overproducer lacking HtrB), was preincubated and then incubated for another 60 min in parallel. At the times indicated following the preincubation, 5-µl portions of each reaction were spotted onto Silica Gel 60 thin layer chromatography plates. The plates were developed, and radioactive spots were detected as in Fig. 2. Arrows indicate the locations of the substrate, (Kdo)2-[4'-32P]lipid IVA, and the two predominant acylation products (a and b).
[View Larger Version of this Image (69K GIF file)]


Specific Activity of MsbB in Extracts of Mutants and Plasmid-bearing Strains

A direct assay for MsbB was developed using 25 µM (Kdo)2-(lauroyl)-[4'-32P]lipid IVA as the acceptor and 25 µM acyl-ACP as the donor (see "Experimental Procedures"). Acylation was detected by thin layer chromatography and PhosphorImager analysis as in Fig. 4. With the direct assay, the specific activity of MsbB in extracts of wild-type cells was ~0.3 nmol/min/mg, but in extracts of msbB-deficient mutants, the activity was below the limits of detection (~0.03 nmol/min/mg). Overexpression of msbB+ on multi-copy hybrid plasmids resulted in ~100-fold higher specific activity of MsbB in cell extracts or membranes compared with wild-type, as shown in Table II. The large size of the observed effects on MsbB-specific activity supports the proposal that msbB is the structural gene encoding the MsbB acyltransferase.

Table II.

Purification of MsbB from E. coli MLK53/pBS233

Myristoyl transferase activities were assayed in 50 mM HEPES, pH 7.5, 0.1% Triton X-100, 50 mM NaCl, 25 µM myristoyl-ACP, and 25 µM (Kdo)2-[lauroyl]-[4'-32P]-lipid IVA (2 × 103 dpm/nmol) at 30 °C.


Total volume Total protein Specific activity Yield

ml mg nmol × min-1 × mg-1 %
Membranes 5.0 208 27 100
Triton X-100 extract 24 84 65 96
Triton X-100-insoluble 5.0 90 3.6 6
DEAE-Sepharose 1.5 5.1 640 57

Solubilization and Partial Purification of MsbB

Washed membranes (5 ml) from E. coli MLK53/pBS233 were diluted in 20 mM Tris chloride, pH 7.8, containing 1 mM EDTA and 1 mM EGTA to a final protein concentration of ~17 mg/ml protein (208 mg of protein in a total volume of 12 ml). The membrane suspension was mixed with an equal volume of solubilization buffer, giving final concentrations of 2.5% Triton X-100, 20 mM Tris chloride, pH 7.8, 1 mM EDTA, 1 mM EGTA, 100 mM sodium phosphate, 150 mM NaCl, and 10% glycerol. The solubilization mixture was incubated with slow stirring at 5 °C for 2 h. Insoluble material was removed by centrifugation for 60 min at 170,000 × g at 5 °C. The supernatant was transferred to a new tube and diluted to a final volume of 72 ml with 20 mM Tris chloride, pH 7.8, 1 mM EDTA, and 1 mM EGTA to reduce the NaCl concentration. The solubilized proteins were loaded onto a DEAE-Sepharose CL-6B column (45-ml packed bed-volume) equilibrated in 0.2% Thesit, 20 mM Tris chloride, pH 7.8, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, and 10% glycerol. After washing the column with 140 ml of equilibration buffer, bound proteins were eluted with a 400-ml linear gradient of 50-500 mM NaCl in 0.2% Thesit, 20 mM Tris chloride, pH 7.8, 1 mM EDTA, 1 mM EGTA, and 10% glycerol. The absorbance at 280 nm of each fraction was measured (Fig. 5, open circles), and the four peak fractions (Fig. 5, shaded area) of MsbB activity (filled circles) were pooled. The combined fractions (20 ml) were diluted 4-fold in 20 mM Tris chloride, pH 7.8, 1 mM EDTA, and 1 mM EGTA, and the material was loaded onto a 1.8-ml DEAE-Sepharose CL-6B column, equilibrated as above, to concentrate the sample. The total protein was then eluted into a total volume of 1.5 ml of 0.05% Triton X-100, 20 mM Tris chloride, pH 7.8, 1 mM EDTA, 1 mM EGTA, 200 mM NaCl, and 10% glycerol. The fractionated MsbB was stored in aliquots at -80 °C.


Fig. 5. Partial purification of solubilized, overproduced MsbB on DEAE-Sepharose CL-6B. Triton X-100-solubilized membrane proteins (84 mg) of strain pBS233/MLK53 were applied onto a 45-ml column of Sepharose CL-6B, as described in the text. Proteins were eluted with a linear gradient consisting of 50-500 mM NaCl. Absorbance at 280 nm (open circles) was used as a measure of total protein in each fraction. MsbB acyltransferase activity (solid circles) was assayed using 5-µl samples of a 1:10 dilution of each fraction. The assay (30 °C) contained 25 µM myristoyl-ACP as acyl donor and 25 µM (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (2 × 103 dpm/nmol) as lipid acceptor in a volume of 15 µl. Buffer and detergent concentrations were the same as those described in Fig. 2, except that 50 mM NaCl and 5 mM MgCl2 were also included. Dotted line, calculated NaCl concentration. Shaded area, active fractions that were pooled and concentrated.
[View Larger Version of this Image (20K GIF file)]


Stability and Assay of Purified MsbB

Using DEAE-Sepharose-purified MsbB, we examined the stability and time dependence of product formation, using enzymatically synthesized (Kdo)2-(lauroyl)-[4'-32P]lipid IVA and myristoyl-ACP as the substrates (Fig. 6). In contrast to the significant activation previously observed with HtrB (6), we found that MsbB was slightly inhibited by the presence of 5 mM MgCl2 (Fig. 6). However, 50 mM NaCl was beneficial (Fig. 6), as in the case of HtrB (6), and MsbB was stable to preincubation under assay conditions for 30 min in the presence of NaCl (not shown). The MsbB assay carried out in the presence of 50 mM NaCl displayed excellent linearity with respect to time (Fig. 6) and protein concentration (not shown).


Fig. 6. Effects of MgCl2 and NaCl on msbB-encoded myristoyltransferase activity. DEAE-Sepharose CL-6B purified MsbB was assayed at a protein concentration of 0.1 µg/ml in 20-µl reaction mixtures containing 50 mM HEPES, pH 7.5, 0.1% Triton X-100, 25 µM myristoyl-ACP, and 25 µM (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (2 × 103 dpm/nmol). Open circles, 50 mM NaCl and 5 mM MgCl2 were added to the reaction; open squares, reaction with 5 mM MgCl2 only; open triangles, reaction with 50 mM NaCl only.
[View Larger Version of this Image (17K GIF file)]


Using the improved conditions, the fractions generated in the course of solubilizing and purifying MsbB were reassayed. Table II shows that the final MsbB preparation is purified about 24-fold relative to washed membranes from the overproducing strain employed, and about 2400-fold relative to crude extracts of wild-type cells.

Selectivity of MsbB for Acyl Chain Length

As shown in Fig. 7, DEAE-Sepharose-purified MsbB displays a slight kinetic preference for myristoyl-ACP over lauroyl-ACP. Other acyl donors, including decanoyl-, palmitoyl-, palmitoleoyl-, and (R)-3-hydroxymyristoyl-ACP are inactive as acyl donors when (Kdo)2-(lauroyl)-[4'-32P]lipid IVA is employed as the acceptor (Fig. 7). The virtual absence of activity with decanoyl-ACP is interesting. HtrB does utilize decanoyl-ACP as a donor in vitro at about one-third of the rate of lauroyl-ACP. Given the fact that we have tested the same acyl-ACP preparations with both HtrB (6) and MsbB (Fig. 7), we conclude that the optimal activity of MsbB with various acyl-ACPs under our assay conditions is set approximately two carbons longer than that of HtrB. In living cells, however, the selectivity of HtrB for laurate and of MsbB for myristate must be higher. No decanoate is found in the position normally occupied by laurate on lipid A under ordinary growth conditions in living cells (Fig. 1), and very little laurate is incorporated in place of myristate (11, 25-28).


Fig. 7. Acyl chain length specificity of the msbB-encoded myristoyltransferase. The initial rates of acylation of 25 µM (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (2 × 103 dpm/nmol) were determined at 30 °C using different acyl-acyl carrier proteins as donors (all at 25 µM). In addition to the indicated substrates, the transferase reaction mixtures contained DEAE-Sepharose CL-6B purified MsbB at a concentration of 0.1 µg/ml, 50 mM HEPES, pH 7.5, 0.1% Triton X-100, and 50 mM NaCl. Reactions (20 µl) were incubated at 30 °C. The initial rates of (Kdo)2-(lauroyl)-[4'-32P]lipid IVA acylation were normalized to that observed with myristoyl-acyl carrier protein (14:0) as the acyl donor. The other acyl chains tested were 10:0, decanoate; 12:0, laurate; HO14:0, (R)-3-hydroxymyristate; 16:0, palmitate; 16:1c, palmitoleate.
[View Larger Version of this Image (27K GIF file)]


Selectivity of MsbB for Penta-acylated Lipid A Precursors

The DEAE-Sepharose-purified preparation of MsbB was used to confirm the specificity of the enzyme for the penta-acylated acceptor, first suggested by the results of Fig. 4. As shown in Fig. 8, we compared [4'-32P]lipid IVA, (Kdo)2-[4'-32P]lipid IVA, and (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (each 25 µM) under matched conditions as myristate acceptors. The reactions in the odd-numbered lanes contained myristoyl-ACP, whereas the ones in the even lanes did not. All observed acylations were dependent upon added myristoyl-ACP. Using a concentration of MsbB (0.1 µg/ml) that resulted in 90% acylation of (Kdo)2-(lauroyl)-[4'-32P]lipid IVA to generate (Kdo)2-[4'-32P]lipid A (i.e. product b) in 60 min (Fig. 8, lane 5), we observed only 1-2% acylation of (Kdo)2-[4'-32P]lipid IVA (Fig. 8, lane 3) (product a') and of [4'-32P]lipid IVA (Fig. 8, lane 1) (product c). The slow but measurable acylation of the tetra-acylated acceptor, (Kdo)2-[4'-32P]lipid IVA (Fig. 8, lane 3), with myristate to generate (Kdo)2-[myristoyl]-[4'-32P]lipid IVA (i.e. product a') (proposed structure in Fig. 1) probably explains why overexpression of msbB+ suppresses the temperature sensitivity of strains defective in htrB (3).


Fig. 8. Lipid acceptor specificity of the msbB-encoded acyltransferase. DEAE-Sepharose CL-6B purified MsbB was used at 0.1 µg/ml in reaction mixtures containing 50 mM HEPES, pH 7.5, 0.1% Triton X-100, 50 mM NaCl, and 25 µM of one of the following acceptor lipids: lanes 1 and 2, [4'-32P]lipid IVA (2 × 103 dpm/nmol); lanes 3 and 4, (Kdo)2-[4'-32P]lipid IVA (1 × 103 dpm/nmol); lanes 5 and 6, (Kdo)2-(lauroyl)-[4'-32P]lipid IVA (2 × 103 dpm/nmol). The reactions (10 µl) were incubated at 30 °C for 60 min either with (lanes 1, 3, and 5) or without (lanes 2, 4, and 6) 25 µM myristoyl-ACP. Arrows indicate migration of lipid substrates and generated products, a', (Kdo)2-[myristoyl]-[4'-32P]lipid IVA and b, (Kdo)2-[4'-32P]lipid A. Proposed structures are shown in Fig. 1.
[View Larger Version of this Image (54K GIF file)]


State of Lipid A Acylation in msbB- and htrB-deficient Mutants and the Effect of Plasmids Bearing msbB+

In previous studies (24), we described a simple, radiochemical method for determining the lipid A content of E. coli. Our procedure involves the labeling of cells with 32Pi, followed by Bligh-Dyer extraction of the glycerophospholipids (24). Next, the cell residue is treated with O.2 M HCl at 100 °C to release all the lipid A moieties of lipopolysaccharide as a series of 4'-monophosphates (24). These compounds are separated into hexa-acylated, penta-acylated, and tetra-acylated species, using silica gel thin layer chromatography (24), and they can be detected by autoradiography or PhosphorImager analysis.

As shown in Fig. 9 (lanes 2 and 3), the lipid A-derived 4'-monophosphates of wild-type cells, labeled for 3 h at either 30 or 42 °C in LB broth (15) with 32Pi, consist mostly of hexa-acylated, some penta-acylated, and a few tetra-acylated forms. The relative abundance of the hexa-acylated species may be underestimated slightly by our procedure because of partial deacylation caused by the acid hydrolysis (24). However, strains defective in msbB yield mostly penta-acylated 4'-monophosphates with only minor amounts of the tetra-acylated species at both 30 or 42 °C (Fig. 9, lanes 4 and 5), consistent with the proposed function of MsbB (Fig. 1). Under nonpermissive conditions (42 °C), strains defective in htrB or in both htrB and msbB (Fig. 9, lanes 7 and 9, respectively) yield mostly tetra-acylated lipid A 4'-monophosphates. Interestingly, when grown at 30 °C, these mutants do generate significant amounts of penta-acylated and even some hexa-acylated forms (Fig. 9, lanes 6 and 8), the origin of which is not entirely clear (see "Discussion"). However, when msbB+ is overexpressed in htrB-deficient cells, growth and considerable amounts of additional penta-acylated 4'-monophosphates are restored at 42 °C (Fig. 9, lane 11 versus lane 7). These observations support the view that high level overexpression of MsbB bypasses the need for HtrB action prior to MsbB-catalyzed acylation. Rapid cell growth apparently requires that a critical fraction of the lipid A moieties of lipopolysaccharide be at least penta-acylated. The enzymatic source of these acylations seems not to be as important.


Fig. 9. Extent of lipid A acylation in wild-type and mutant strains determined by 32Pi labeling. Cells of each of the indicated strains were grown at 30 °C on LB broth until A600 had reached ~0.1. Each of the cultures was divided into two 5-ml portions, and 32Pi (5 µCi/ml) was added to both. One culture was grown for 3 h at 30 °C, and the other was grown for 3 h at 42 °C. After this period to allow for uniform labeling of the cellular lipids, the lipid A 4'-monophosphate fractions were isolated by a modification of the procedure of Galloway and Raetz (24). Approximately 1000 cpm of isolated lipid A [32P-4']monophosphates was applied to each lane of a Silica Gel 60 thin layer chromatography plate. The plate was developed in the solvent chloroform, pyridine, 88% formic acid, water (50:50:16:5, v/v). The plate was then dried and exposed overnight to a PhosphorImager screen. The positions of the hexa-acylated, penta-acylated, and tetra-acylated [32P-4']monophosphates, as well as the origin, are indicated. Lanes 1 and 12 show the position of a tetra-acylated [32P-4']monophosphate standard that was generated by acid hydrolysis of [4'-32P]lipid IVA. Even lanes are 4'-monophosphates from cells grown at 30 °C and odd lanes from cells grown at 42 °C. The strains are as follows: lanes 2 and 3, W3110; lanes 4 and 5, MLK1067; lanes 6 and 7, MLK53; lanes 8 and 9, MLK986; lanes 10 and 11, MLK53/pBS233.
[View Larger Version of this Image (82K GIF file)]



DISCUSSION

As shown by the results of Figs. 2, 3, 4, 8, and 9, msbB encodes a distinct acyltransferase of lipid A assembly that functions optimally after laurate incorporation by HtrB has occurred. The proposed intermediates generated by MsbB and HtrB are shown in Fig. 1. These structural proposals are based on what is known about lipid A released from E. coli lipopolysaccharide by acid hydrolysis (11, 25-28). The proposed structures also are in accord with the molecular weights of (Kdo)2-lipid IVA acylation products generated previously with crude cell extracts (7). The lauroyl and myristoyl groups are attached by HtrB and MsbB to the lipid IVA moiety of (Kdo)2-lipid IVA (7). However, the structures of the acylated derivatives of (Kdo)2-lipid IVA generated using homogeneous preparations of HtrB and MsbB remain to be established unequivocally.

Besides HtrB and MsbB, there are at least two additional enzymes that may be able to acylate (Kdo)2-lipid IVA in E. coli extracts. One of these transfers palmitate from the 1-position of a glycerophospholipid to the (R)-3-hydroxy moiety of the N-linked (R)-3-hydroxymyristate of the proximal glucosamine unit (20). The palmitoyltransferase has not been purified, and the gene encoding it is unknown. In addition, we have recently obtained evidence for a cold shock-induced enzyme that transfers palmitoleate from palmitoleoyl-ACP to (Kdo)2-lipid IVA.3 In living cells of E. coli and Salmonella typhimurium, cold shock causes the incorporation of an equivalent of palmitoleate into lipid A at the expense of laurate (29, 30). Palmitoleate is not incorporated into (Kdo)2-lipid IVA by purified HtrB (6).

As shown in Fig. 9, E. coli mutants defective in htrB or in both htrB and msbB contain lipid A moieties that are mainly tetra-acylated when cells are grown at 42 °C for 3 h. The presence of excess msbB+ on hybrid plasmids maintained at high copy number restores some penta-acylated lipid A species (Fig. 9) and suppresses the temperature-sensitive growth phenotype associated with htrB mutations (3). These findings suggest that the slow rate of acylation of (Kdo)2-lipid IVA catalyzed by MsbB (Fig. 8, product a') may be sufficient to generate a significant number of acyloxyacyl moieties when MsbB is overproduced in htrB-deficient cells. We presume that (Kdo)2-(myristoyl)-lipid IVA, having the proposed structure shown at the bottom of Fig. 1, is being generated when the htrB mutation is suppressed by overexpression of msbB+.

E. coli mutants defective in htrB or in both htrB and msbB do contain some penta- and hexa-acylated lipid A species when grown at 30 °C (Fig. 9). These species might arise by action of the palmitoyltransferase (20) or the cold-induced palmitoleoyltransferase noted above. To determine the origin of these more highly acylated lipid A species present in mutants defective in both htrB and msbB, it will be necessary to carry out additional chemical analyses. Preliminary results with laser desorption mass spectrometry4 indicate that lipid A isolated from mutants defective in both htrB and msbB grown at 30 °C consists of a mixture of tetra-acylated and penta-acylated forms. Both forms contain four hydroxymyristoyl chains, but the penta-acylated species contains an additional palmitate or palmitoleate.

The effects of the msbA multi-copy suppressor (5) on the extent of acylation of the lipid A moieties present in mutants defective in both htrB and msbB remain to be examined. Recently, Polissi and Georgopoulos (31) have found that lipopolysaccharide accumulates in the inner membranes of htrB- deficient mutants. Introduction of both msbA+ and orfE+ (an essential downstream gene of unknown function) on hybrid plasmids partially restored-deficient translocation of lipopolysaccharide to the outer membrane in htrB mutants (31). Insertion mutations that conditionally inactivate both msbA and orfE also appear to accumulate lipopolysaccharide in their inner membranes (31). If msbA is really involved in lipid A export, as anticipated because of its sequence similarity to mammalian Mdr proteins, one should see no restoration of lipid A acylation upon suppression of htrB-msbB- mutants by msbA+. If msbA, like msbB, encodes a distinct acyltransferase, however, then the extent of lipid A acylation would be increased when mutants defective in both htrB and msbB are complemented by msbA.

A search of genome data bases indicates that H. influenzae contains htrB and msbB homologues (8). Based on mass spectrometry of lipid A isolated from htrB mutants of H. influenzae (8), it is likely that HtrB function is conserved in this organism. All known HtrB and MsbB sequences contain the peptide LCFP in the vicinity of residue 70.

The identification of the genes that are responsible for the early and late acylations of lipid A should facilitate the construction of E. coli strains possessing greatly reduced or altered endotoxin activities. The msbB insertion mutations described by Somerville et al. (13) reduce the ability of intact E. coli to activate macrophages by several orders of magnitude. By further modifying the structure and composition of E. coli lipid A, it may be possible to create strains with virtually no endotoxin activity. For instance, substitution of E. coli lpxA with Pseudomonas lpxA (32), coupled with deletion of msbB, would result in the generation of a lipid A with considerable similarity to that of Rhodobacter sphaeroides (33, 34). Lipid A of R. sphaeroides actually antagonizes the activities of wild-type E. coli endotoxin (33, 34). Such E. coli mutants, if viable, might be very useful for the expression and preparation of proteins intended for injection into animals, since quantitative removal of lipopolysaccharide would not be as critical. Modification of the structure of lipid A in living bacterial cells might also provide new insights into the functions of lipid A in outer membrane biogenesis and during infection of animals.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant GM-51310 (to C. R. H. R. at Duke University).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 919-684-5326; E-mail: Raetz{at}BCHM.Biochem.Duke.edu.
1   The abbreviation used is: Kdo, 3-deoxy-D-manno-octulosonic acid.
4   S. Snyder, I. Kaltashov, and C. R. H. Raetz, unpublished observations.
2   S. Carty and C. R. H. Raetz, manuscript in preparation.
3   S. M. Carty and C. R. H. Raetz, unpublished observations.

ACKNOWLEDGEMENT

We thank Dr. Margaret Karow for providing the htrB- and msbB-related strains listed in Table I and for many helpful discussions.


REFERENCES

  1. Karow, M., Fayet, O., Cegielska, A., Ziegelhoffer, T., and Georgopoulos, C. (1991) J. Bacteriol. 173, 741-750 [Medline] [Order article via Infotrieve]
  2. Karow, M., and Georgopoulos, C. (1991) Mol. Microbiol. 5, 2285-2292 [Medline] [Order article via Infotrieve]
  3. Karow, M., and Georgopoulos, C. (1992) J. Bacteriol. 174, 702-710 [Abstract]
  4. Karow, M., Fayet, O., and Georgopoulos, C. (1992) J. Bacteriol. 174, 7407-7418 [Abstract]
  5. Karow, M., and Georgopoulos, C. (1993) Mol. Microbiol. 7, 69-79 [Medline] [Order article via Infotrieve]
  6. Clementz, T., Bednarski, J. J., and Raetz, C. R. H. (1996) J. Biol. Chem. 271, 12095-12102 [Abstract/Free Full Text]
  7. Brozek, K. A., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 15410-15417 [Abstract/Free Full Text]
  8. Lee, N.-G., Sunshine, M. G., Engstrom, J. J., Gibson, B. W., and Apicella, M. A. (1995) J. Biol. Chem. 270, 27151-27159 [Abstract/Free Full Text]
  9. Oude-Elferink, R. P. J., Ottenhoff, R., van Wijland, M., Smit, J. J. M., Schinkel, A. H., and Groen, A. K. (1995) J. Clin. Invest. 95, 31-38 [Medline] [Order article via Infotrieve]
  10. Osborn, M. J. (1979) in Bacterial Outer Membranes (Inouye, M., ed), pp. 15-34, Wiley Interscience, New York
  11. Raetz, C. R. H. (1990) Annu. Rev. Biochem. 59, 129-170 [CrossRef][Medline] [Order article via Infotrieve]
  12. Raetz, C. R. H. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C. E. A., ed), 2nd Ed., Vol. 1, pp. 1035-1063, American Society for Microbiology, Washington, D. C.
  13. Somerville, J. E., Jr., Cassiano, L., Bainbridge, B., Cunningham, M. D., and Darveau, R. P. (1996) J. Clin. Invest. 97, 359-365 [Abstract/Free Full Text]
  14. Clementz, T., Bednarski, J., and Raetz, C. R. H. (1995) FASEB J. 9, 1311 [Abstract/Free Full Text]
  15. Miller, J. R. (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  16. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1989) Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York
  17. Raetz, C. R. H., Purcell, S., Meyer, M. V., Qureshi, N., and Takayama, K. (1985) J. Biol. Chem. 260, 16080-16088 [Abstract/Free Full Text]
  18. Brozek, K. A., Hosaka, K., Robertson, A. D., and Raetz, C. R. H. (1989) J. Biol. Chem. 264, 6956-6966 [Abstract/Free Full Text]
  19. Belunis, C. J., and Raetz, C. R. H. (1992) J. Biol. Chem. 267, 9988-9997 [Abstract/Free Full Text]
  20. Brozek, K. A., Bulawa, C. E., and Raetz, C. R. H. (1987) J. Biol. Chem. 262, 5170-5179 [Abstract/Free Full Text]
  21. Hampton, R. Y., and Raetz, C. R. H. (1992) Methods Enzymol. 209, 466-475 [Medline] [Order article via Infotrieve]
  22. Nishijima, M., and Raetz, C. R. H. (1979) J. Biol. Chem. 254, 7837-7844 [Medline] [Order article via Infotrieve]
  23. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85 [Medline] [Order article via Infotrieve]
  24. Galloway, S. M., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 6394-6402 [Abstract/Free Full Text]
  25. Qureshi, N., Cotter, R. J., and Takayama, K. (1986) J. Microbiol. Methods 5, 65-77
  26. Qureshi, N., Takayama, K., Mascagni, P., Honovich, J., Wong, R., and Cotter, R. J. (1988) J. Biol. Chem. 263, 11971-11976 [Abstract/Free Full Text]
  27. Karibian, D., Deprun, C., and Caroff, M. (1993) J. Bacteriol. 175, 2988-2993 [Abstract]
  28. Myers, K. R., Ulrich, J. T., Qureshi, N., Takayama, K., Wang, R., Chen, L., Emary, W. B., and Cotter, R. J. (1992) Bioconjugate Chem. 3, 540-548 [Medline] [Order article via Infotrieve]
  29. Van Alphen, L., Lugtenberg, B., Rietschel, E. T., and Mombers, C. (1979) Eur. J. Biochem. 101, 571-579 [Medline] [Order article via Infotrieve]
  30. Wollenweber, H.-W., Schlecht, S., Lüderitz, O., and Rietschel, E. T. (1983) Eur. J. Biochem. 130, 167-171 [Abstract]
  31. Polissi, A., and Georgopoulos, C. (1996) Mol. Microbiol. 20, 1221-1233 [Medline] [Order article via Infotrieve]
  32. Williamson, J. M., Anderson, M. S., and Raetz, C. R. H. (1991) J. Bacteriol. 173, 3591-3596 [Medline] [Order article via Infotrieve]
  33. Takayama, K., Qureshi, N., Beutler, B., and Kirkland, T. N. (1989) Infect. Immun. 57, 1336-1338 [Medline] [Order article via Infotrieve]
  34. Golenbock, D. T., Hampton, R. Y., Qureshi, N., Takayama, K., and Raetz, C. R. H. (1991) J. Biol. Chem. 266, 19490-19498 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.